pramipexole sustained release (LY03401)
/ Luye Group
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
April 19, 2019
Registration application of Luye Pharma’s new drug for Parkinson’s disease accepted by China’s NMPA
(Luye Pharma Press Release)
- "Luye Pharma Group has announced that its application to register Pramipexole Dihydrochloride Sustained Release Tablet for the treatment of Parkinson's disease has been accepted by China’s National Medical Products Administration (NMPA)....Pramipexole sustained release tablets are still in their infancy stage of development in China and thus have great market potential."
Non-US regulatory
1 to 1
Of
1
Go to page
1